Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
Titel:
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
Auteur:
Armstrong, Andrew J. Halabi, Susan Healy, Patrick Alumkal, Joshi J. Winters, Carolyn Kephart, Julie Bitting, Rhonda L. Hobbs, Carey Soleau, Colleen F. Beer, Tomasz M. Slottke, Rachel Mundy, Kelly Yu, Evan Y. George, Daniel J.